secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0001819790-24-000119
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus appoints Elizabeth Yeu as CMO; she resigns from board
------------------------------------------------------------

- Dr. Yeu appointed Chief Medical Officer effective Nov 4, 2024; resigned from Board same date.
- Annual base salary of $480,000, $25,000 signing bonus, and 45% annual incentive bonus.
- Granted 27,278 RSUs vesting 25% annually over four years, and option for 41,074 shares.
- Severance includes 12 months salary and benefits; accelerated vesting on change in control.
- Dr. Yeu previously served as board member since Dec 2021 and consulting Chief Medical Advisor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000181979024000119/0001819790-24-000119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000181979024000119/tars-20241101.htm
  HTML page:      https://secwatch.observer/filing/0001819790-24-000119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer